Compare Abeona Therapeutics Inc (ABEO) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs CSX Corporation — how do they compare? Abeona Therapeutics Inc trades at $5.58 (market cap $319.66M), while CSX Corporation trades at $47.3 (market cap $88.73B). The key difference: CSX Corporation is far larger — about 277.6× Abeona Therapeutics Inc's market cap, and CSX Corporation pays a 1.17% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abeona Therapeutics Inc for 22 Days and CSX Corporation for 54 Days on average.
| ABEO | CSX | |
|---|---|---|
Market Cap | $319.66M | $88.73B |
Volume | 3,459,993 | 9,354,060 |
Sector | Health | Industrials |
52-Week High | $7.46 | $53.21 |
52-Week Low | $4.17 | $32.98 |
Typical Hold Time | 22 Days | 54 Days |
Enterprise Value | $192.70M | $106.70B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abeona Therapeutics (ABEO) trades at $5.59, up 4.1% on the day, with a bearish technical outlook per moving averages. The company shows mixed fundamentals: a low P/E of 7.86 and EV/EBITDA of 3.82 suggest undervaluation, but negative net income margin of -246.42% and ROE of -43.13% highlight profitability challenges. Recent news includes a fraud investigation by Pomerantz Law Firm and expansion of treatment centers for ZEVASKYN. Q2 2026 earnings missed expectations, with revenue of $11.4 million but operational setbacks.
The stock presents high risk with speculative upside. Analyst consensus is bullish with a $17.67 price target (66.7% buy ratings), but negative cash flows, ongoing legal probes, and execution risks in therapy rollout pose significant threats. Investors should weigh potential regulatory approvals and revenue growth against substantial operational and financial instability.
CSX trades at $47.10, down 1.67% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The stock faces headwinds from declining revenue and net income margins over the past three years, though 2026 projections suggest improvement. Analyst consensus remains positive with a $51.06 price target, supported by institutional buying activity and a stable dividend payment scheduled for September 2026.
The outlook for CSX is cautiously optimistic given strong institutional support and projected earnings recovery, but investors should monitor ongoing revenue pressure and high valuation multiples. Key risks include economic sensitivity and competitive pressures in the railroad industry, while technical weakness near current support levels warrants attention for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
